Sodium-[o-[(2,6-dichlorophenyl)-amino]- phenyl]-acetate (DrugBank: Acetate)
43 diseases告示番号 | 疾患名(ページ内リンク) | 臨床試験数 |
---|---|---|
1 | 球脊髄性筋萎縮症 | 0 |
2 | 筋萎縮性側索硬化症 | 0 |
6 | パーキンソン病 | 0 |
10 | シャルコー・マリー・トゥース病 | 0 |
13 | 多発性硬化症/視神経脊髄炎 | 0 |
35 | 天疱瘡 | 0 |
40 | 高安動脈炎 | 0 |
46 | 悪性関節リウマチ | 1 |
49 | 全身性エリテマトーデス | 0 |
51 | 全身性強皮症 | 0 |
60 | 再生不良性貧血 | 0 |
64 | 血栓性血小板減少性紫斑病 | 0 |
67 | 多発性嚢胞腎 | 0 |
70 | 広範脊柱管狭窄症 | 0 |
71 | 特発性大腿骨頭壊死症 | 0 |
73 | 下垂体性TSH分泌亢進症 | 0 |
75 | クッシング病 | 0 |
76 | 下垂体性ゴナドトロピン分泌亢進症 | 0 |
78 | 下垂体前葉機能低下症 | 0 |
79 | 家族性高コレステロール血症(ホモ接合体) | 0 |
81 | 先天性副腎皮質酵素欠損症 | 0 |
83 | アジソン病 | 0 |
85 | 特発性間質性肺炎 | 0 |
86 | 肺動脈性肺高血圧症 | 0 |
88 | 慢性血栓塞栓性肺高血圧症 | 0 |
90 | 網膜色素変性症 | 0 |
96 | クローン病 | 0 |
97 | 潰瘍性大腸炎 | 0 |
113 | 筋ジストロフィー | 0 |
145 | ウエスト症候群 | 0 |
156 | レット症候群 | 0 |
162 | 類天疱瘡(後天性表皮水疱症を含む。) | 0 |
171 | ウィルソン病 | 0 |
206 | 脆弱X症候群 | 0 |
222 | 一次性ネフローゼ症候群 | 0 |
224 | 紫斑病性腎炎 | 0 |
225 | 先天性腎性尿崩症 | 0 |
227 | オスラー病 | 0 |
235 | 副甲状腺機能低下症 | 0 |
265 | 脂肪萎縮症 | 0 |
288 | 自己免疫性後天性凝固因子欠乏症[自己免疫性出血病XIII (~2017.3)] | 0 |
298 | 遺伝性膵炎 | 0 |
299 | 嚢胞性線維症 | 0 |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | EUCTR2004-001234-17-DE (EUCTR) | 20/03/2006 | 14/12/2005 | Double-blind, triple dummy, parallel-group, randomized, six-month study to compare celecoxib (200 mg BID) with diclofenac SR (75 mg BID) plus omeprazole (20 mg QD) for gastrointestinal events in subjects with osteoarthritis and rheumatoid arthritis at high-risk of gastrointestinal adverse events - CONDOR | Double-blind, triple dummy, parallel-group, randomized, six-month study to compare celecoxib (200 mg BID) with diclofenac SR (75 mg BID) plus omeprazole (20 mg QD) for gastrointestinal events in subjects with osteoarthritis and rheumatoid arthritis at high-risk of gastrointestinal adverse events - CONDOR | Treatment of osteoarthritis (OA) and/or rheumatoid arthritis (RA) in high GI risk patients MedDRA version: 8.0;Level: LLT;Classification code 10039073 | Trade Name: Celebrex 200 mg Hartkapseln Product Name: Celebrex INN or Proposed INN: Celecoxib Other descriptive name: 4-[5-(4-methylphenyl)-3-(trifluoromethyl)- 1H-pyrazol-1-yl] benzenesulfonamide Trade Name: Voltarol SR Product Name: Voltarol SR INN or Proposed INN: Diclofenac sodium Other descriptive name: sodium-[o-[(2,6-dichlorophenyl)-amino]- phenyl]-acetate Trade Name: Losec Capsules 20 mg Product Name: Losec INN or Proposed INN: Omeprazole Other descriptive name: benzimidazole,5-methoxy-2-[[(4-methoxy- 3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1 H-benzimidazole | Pfizer Pharma GmbH | NULL | Not Recruiting | Female: yes Male: yes | 4402 | Portugal;Estonia;Czech Republic;Greece;Spain;Ireland;Lithuania;Latvia;Germany;United Kingdom;Sweden |